ARX788 is named as an intervention in 2 current clinical trials in our USA and China registers. None are recruiting at the moment. The most common phase is Phase 2. The sponsor with the most trials is Ambrx, Inc (1). The most-studied condition is HER2 Positive Metastatic Breast Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
NCT05426486 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer
|
Phase 2/3 | Active, closed | Caigang Liu | China |
|
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NCT04829604 · ClinicalTrials.gov ↗ · HER2 Positive Metastatic Breast Cancer
|
Phase 2 | Active, closed | Ambrx, Inc. | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Ambrx, Inc. | 1 |
| Caigang Liu | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 0 |
| Clinical trials in China | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA and China registers name ARX788 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Ambrx, Inc (1) and Caigang Liu (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ARX788 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ARX788 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ARX788 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.